Literature DB >> 33857906

Artificial intelligence for cellular phenotyping diagnosis of nasal polyps by whole-slide imaging.

Qingwu Wu1, Jianning Chen2, Yong Ren3, Huijun Qiu4, Lianxiong Yuan5, Huiyi Deng4, Yana Zhang4, Rui Zheng4, Haiyu Hong6, Yueqi Sun7, Xinyue Wang4, Xuekun Huang4, Chunkui Shao2, Haotian Lin8, Lanqing Han9, Qintai Yang10.   

Abstract

BACKGROUND: artificial intelligence (AI) for cellular phenotyping diagnosis of nasal polyps by whole-slide imaging (WSI) is lacking. We aim to establish an AI chronic rhinosinusitis evaluation platform 2.0 (AICEP 2.0) to obtain the proportion of inflammatory cells for cellular phenotyping diagnosis of nasal polyps and to explore the clinical significance of different phenotypes of nasal polyps on the WSI.
METHODS: a total of 453 patients were enrolled in our study. For the development of AICEP 2.0, 179 patients (WSIs) were obtained from the Third Affiliated Hospital of Sun Yat-Sen University (3HSYSU) from January 2008 to December 2018. A total of 24,625 patches were automatically extracted from the regions of interest under a 400× HPF by Openslide and the number of inflammatory cells in these patches was counted by two pathologists. For the application of AICEP 2.0 in a prospective cohort, 158 patients aged 14-70 years old with chronic rhinosinusitis with nasal polyps (CRSwNP) who had undergone endoscopic sinus surgery at 3HSYSU from June 2020 to December 2020 were included for preoperative demographic characteristics. For the application of AICEP 2.0 in a retrospective cohort, 116 patients with CRSwNP who had undergone endoscopic sinus surgery from May 2016 to June 2017 were enrolled for the recurrence rate. The proportion of inflammatory cells of these patients on WSI was calculated by our AICEP 2.0.
FINDINGS: for AICEP 2.0, the mean absolute errors of the ratios of eosinophils, lymphocytes, neutrophils, and plasma cells were 1.64%, 2.13%, 1.06%, and 1.22%, respectively. The four phenotypes of nasal polyps were significantly different in clinical characteristics (including asthma, itching, sneezing, total IgE, peripheral eosinophils%, tissue eosinophils%, tissue neutrophils%, tissue lymphocytes%, tissue plasma cells%, and recurrence rate; P <0.05), but there were no significant differences in age distribution, onset time, total VAS score, Lund-Kennedy score, or Lund-Mackay score. The percentage of peripheral eosinophils was positively correlated with the percentage of tissue eosinophils (r = 0.560, P <0.001) and negatively correlated with tissue lymphocytes% (r = -0.489, P <0.001), tissue neutrophils% (r = -0.225, P = 0.005), and tissue plasma cells% (r = -0.266, P = 0.001) in WSIs.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Artificial intelligence; Cellular phenotype; Chronic rhinosinusitis; Deep learning; Nasal polyps; Whole-slide imaging

Year:  2021        PMID: 33857906     DOI: 10.1016/j.ebiom.2021.103336

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


  3 in total

Review 1.  Artificial intelligence, machine learning, and deep learning in rhinology: a systematic review.

Authors:  Antonio Mario Bulfamante; Francesco Ferella; Austin Michael Miller; Cecilia Rosso; Carlotta Pipolo; Emanuela Fuccillo; Giovanni Felisati; Alberto Maria Saibene
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-19       Impact factor: 3.236

Review 2.  Role of Respiratory Epithelial Cells in Allergic Diseases.

Authors:  Constanze A Jakwerth; Jose Ordovas-Montanes; Simon Blank; Carsten B Schmidt-Weber; Ulrich M Zissler
Journal:  Cells       Date:  2022-04-20       Impact factor: 7.666

3.  Chinese Central Compartment Atopic Disease: The Clinical Characteristics and Cellular Endotypes Based on Whole-Slide Imaging.

Authors:  Weifeng Kong; Qingwu Wu; Yubin Chen; Yong Ren; Weihao Wang; Rui Zheng; Huiyi Deng; Tian Yuan; Huijun Qiu; Xinyue Wang; Xin Luo; Xuekun Huang; Qintai Yang; Gehua Zhang; Yana Zhang
Journal:  J Asthma Allergy       Date:  2022-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.